288 related articles for article (PubMed ID: 34274291)
21. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.
Davids MS; Sharman JP; Ghia P; Woyach JA; Eyre TA; Jurczak W; Siddiqi T; Miranda P; Shahkarami M; Butturini A; Emeribe U; Byrd JC
Blood Adv; 2024 Jul; 8(13):3345-3359. PubMed ID: 38640349
[TBL] [Abstract][Full Text] [Related]
22. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
23. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
25. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Novak J; Strugov V; Gill D; Gribben JG; Kwei K; Dai S; Hsu E; Dean JP; Flinn IW
Haematologica; 2022 Sep; 107(9):2108-2120. PubMed ID: 35021599
[TBL] [Abstract][Full Text] [Related]
27. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
28. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
[TBL] [Abstract][Full Text] [Related]
29. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
[TBL] [Abstract][Full Text] [Related]
30. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
[TBL] [Abstract][Full Text] [Related]
31. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W
J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172
[TBL] [Abstract][Full Text] [Related]
32. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
33. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Huang Q; Deering KL; Harshaw Q; Leslie LA
Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
[TBL] [Abstract][Full Text] [Related]
34. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
35. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract][Full Text] [Related]
36. Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis.
Chen PH; Ho CL; Lin C; Wu YY; Huang TC; Tu YK; Lee CH
J Clin Med; 2019 May; 8(5):. PubMed ID: 31126075
[TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
38. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
[TBL] [Abstract][Full Text] [Related]
39. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
40. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Burger JA; Robak T; Demirkan F; Bairey O; Moreno C; Simpson D; Munir T; Stevens DA; Dai S; Cheung LWK; Kwei K; Lal I; Hsu E; Kipps TJ; Tedeschi A
Leuk Lymphoma; 2022 Jun; 63(6):1375-1386. PubMed ID: 35014928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
